Updated:
SIGA Technologies
SIGA Technologies, led by CEO Diem Nguyen, develops TPOXX, the FDA-approved smallpox antiviral stockpiled by the US government.
SIGA Technologies
SIGA Technologies was founded in 1995 and is led by CEO Diem Nguyen. The company's commercial identity is inseparable from its flagship product, TPOXX (tecovirimat), an antiviral developed under the US government's biodefense preparedness framework following the 9/11 and anthrax attacks. Its wealth origin and operating model are tied to federal procurement, principally through the Biomedical Advanced Research and Development Authority (BARDA). The firm's strategy centers on a single asset deployed across two threat-response categories. TPOXX holds FDA approval for smallpox and is maintained in the Strategic National Stockpile (per public record). A second application targets mpox, where SIGA has supplied TPOXX for clinical trials and emergency use globally, including in the European Union, the United Kingdom, and multiple African nations. The company does not operate a broad pipeline, relying instead on procurement contracts, such as a $113 million BARDA order for intravenous TPOXX announced in 2023 (per the firm, November 2023). SIGA keeps a lean commercial footprint, with its headquarters in New York and manufacturing outsourced to contract partners. The company has periodically returned capital to shareholders through significant special dividends, a structural feature that distinguishes it from reinvestment-heavy biotechs. A recent operational milestone was the expanded US government contract award for oral TPOXX, valued at up to $415 million, announced in August 2024 (per the firm, August 2024). SIGA's structural differentiator is its codependence with a single government customer. The binary nature of biodefense stockpiling means revenue is lumpy and tied to geopolitical threat assessment, rather than traditional drug-market dynamics. This creates a cash-rich, pipeline-thin profile that functions more like a sovereign health-security partner than a diversified pharmaceutical company.
General information
Firm type
Asset Manager
Year founded
1995
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Diem Nguyen
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at SIGA Technologies?
SIGA is an operating biopharmaceutical company, not a family office or investment firm. Capital allocation decisions are made by the executive management team, led by CEO Diem Nguyen, and approved by the board of directors. The company's primary financial decisions involve deploying cash reserves toward manufacturing, shareholder dividends, and limited pipeline development.
How does SIGA generate its revenue?
SIGA's revenue comes primarily from US government procurement contracts for its smallpox antiviral, TPOXX, which is held in the Strategic National Stockpile. The Biomedical Advanced Research and Development Authority has placed multiple large-volume orders over the years. The company also sells TPOXX internationally for mpox response, but the US government remains the dominant customer.
Is TPOXX effective against mpox?
TPOXX is approved by the FDA for smallpox and has been used for mpox under expanded-access protocols and clinical trials. The company has supplied TPOXX to the US government, European Union, United Kingdom, and African nations for mpox response, but regulatory approvals for mpox specifically vary by jurisdiction. Clinical data collection is ongoing.
How does SIGA compare to a traditional biotech company?
SIGA differs from most biotechs by concentrating on a single approved product sold primarily to one government customer. It does not maintain a broad drug pipeline, spend heavily on R&D, or rely on venture funding. This National Stockpile model produces lumpy revenue and allows the company to return cash to shareholders through dividends rather than continuous reinvestment.
What is the relationship between SIGA and the US government's BARDA?
BARDA has been SIGA's primary partner and customer for over a decade, funding the development of TPOXX and repeatedly contracting for its delivery into the Strategic National Stockpile. The relationship is contractual, not equity-based, but SIGA's commercial viability remains highly dependent on BARDA's continued assessment of smallpox and mpox as national biosecurity threats.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: